Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Uno Healthcare›
Analysis
AddedFeb 16, 2024
UpdatedJun 11, 2026
Uno Healthcare

Uno Healthcare

Uno Healthcare is a pharmaceutical distributor specializing in the importation of hard-to-find medications to Brazil and Latin America.

HQ
Doral, FL, US
Founded
1996
Loading
Overview
Analysis
Compare
Employees
News
Website

Contents

  1. 01Products & Services
  2. 02Market Outlook
  3. 03Competitive Strengths
  1. 01Products & Services
  2. 02Market Outlook
  3. 03Competitive Strengths

Product Overview

Uno Healthcare provides pharmaceutical importation and distribution services with a catalog of over 200,000 products. The company's core offerings include specialty medications for rare diseases, oncology treatments, vaccines, hematology drugs, and pulmonary therapies.

Uno Healthcare manages the complete importation process for patients and healthcare institutions in Brazil, including document validation, prescription review, regulatory compliance with ANVISA requirements, international payment processing, and temperature-controlled shipping with real-time tracking.

Market Outlook

The market for pharmaceutical importation services in Brazil continues to grow as patients and healthcare providers seek access to medications not available domestically. Regulatory frameworks including ANVISA Resolution RDC No. 81/2008 govern the importation process for personal use and institutional procurement.

Uno Healthcare serves governmental health agencies, hospitals, clinics, and individual patients, positioning itself to benefit from increasing demand for specialty pharmaceuticals, orphan drugs, and personalized medicine therapies in Latin American markets. The company's established international network and partnerships with biotechnology manufacturers provide a foundation for continued expansion.

Competitive Advantages

Uno Healthcare maintains competitive advantages through its Florida Department of Health licensing, Good Distribution Practice compliance, and established relationships with GMP-certified manufacturers worldwide. The company operates a temperature-controlled warehouse with state-of-the-art cold chain monitoring and backup systems.

Its regulatory expertise includes obtaining marketing approvals and import licenses across multiple countries, while its pharmacovigilance capabilities ensure ongoing product safety monitoring and patient registry management. The company also provides translation services to Spanish and Portuguese to facilitate understanding by healthcare professionals in Latin America.